A citation-based method for searching scientific literature

Xin Luo, Jing Xu, Jianhua Yu, Ping Yi. Front Immunol 2021
Times Cited: 3







List of co-cited articles
5 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
66

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn,[...]. Science 2018
710
66

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Eiichi Sato, Sara H Olson, Jiyoung Ahn, Brian Bundy, Hiroyoshi Nishikawa, Feng Qian, Achim A Jungbluth, Denise Frosina, Sacha Gnjatic, Christine Ambrosone,[...]. Proc Natl Acad Sci U S A 2005
66

Immunotherapy in Ovarian Cancer: Are We There Yet?
Lana E Kandalaft, Kunle Odunsi, George Coukos. J Clin Oncol 2019
35
66

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
T A Chan, M Yarchoan, E Jaffee, C Swanton, S A Quezada, A Stenzinger, S Peters. Ann Oncol 2019
575
66

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Kathleen N Moore, Michael Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Cagatay Taskiran, Katina Robison, Johanna Mäenpää,[...]. J Clin Oncol 2021
21
33

Immune Therapy Opportunities in Ovarian Cancer.
Lana E Kandalaft, Kunle Odunsi, George Coukos. Am Soc Clin Oncol Educ Book 2020
10
33

A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.
Jeffrey S Weber, Mario Sznol, Ryan J Sullivan, Shauna Blackmon, Genevieve Boland, Harriet M Kluger, Ruth Halaban, Antonietta Bacchiocchi, Paolo A Ascierto, Mariaelena Capone,[...]. Cancer Immunol Res 2018
43
33

Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.
Veronica Huber, Viviana Vallacchi, Viktor Fleming, Xiaoying Hu, Agata Cova, Matteo Dugo, Eriomina Shahaj, Roberta Sulsenti, Elisabetta Vergani, Paola Filipazzi,[...]. J Clin Invest 2018
101
33


Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
151
33

Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?
Panagiotis A Konstantinopoulos, Stephen A Cannistra. J Clin Oncol 2021
3
33

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Emese Zsiros, Sarah Lynam, Kristopher M Attwood, Chong Wang, Shanmuga Chilakapati, Eduardo Cortes Gomez, Song Liu, Stacey Akers, Shashikant Lele, Peter J Frederick,[...]. JAMA Oncol 2021
16
33

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, Linhua Zou, Xavier Alvarez, Pui Cheng, Peter Mottram, Melina Evdemon-Hogan, Jose R Conejo-Garcia, Lin Zhang, Matthew Burow,[...]. Nat Med 2004
33

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R Kaufman, Andrew Albright, Jonathan D Cheng, S Peter Kang, Veena Shankaran,[...]. J Clin Invest 2017
33


Use of Circulating Tumor DNA for Cancer Immunotherapy.
Alexandra Snyder, Michael P Morrissey, Matthew D Hellmann. Clin Cancer Res 2019
20
33

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
187
33

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, Kimio Ushijima, Tadashi Kimura, Satoshi Takeuchi, Koji Matsumoto, Kimihiko Ito, Masaki Mandai, Hidekatsu Nakai,[...]. J Clin Oncol 2021
3
33

Regulation of tumor metastasis by myeloid-derived suppressor cells.
Thomas Condamine, Indu Ramachandran, Je-In Youn, Dmitry I Gabrilovich. Annu Rev Med 2015
269
33

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
Janis M Taube, Robert A Anders, Geoffrey D Young, Haiying Xu, Rajni Sharma, Tracee L McMiller, Shuming Chen, Alison P Klein, Drew M Pardoll, Suzanne L Topalian,[...]. Sci Transl Med 2012
33

Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers.
Youn Soo Le, Tae Eung Kim, Byung Kee Kim, Yong Gyu Park, Gyu-Moon Kim, Sung-Bae Jee, Ki Sung Ryu, In-Kyung Kim, Jin Woo Kim. Exp Mol Med 2002
14
33

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
788
33

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Eric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, Amit M Oza, Rebecca Kristeleit, Isabelle-Laure Ray-Coquard, Gary E Richardson, Cristiana Sessa, Kan Yonemori, Susana Banerjee,[...]. Lancet Oncol 2021
9
33

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
33

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
S Y Cindy Yang, Stephanie Lheureux, Katherine Karakasis, Julia V Burnier, Jeffery P Bruce, Derek L Clouthier, Arnavaz Danesh, Rene Quevedo, Mark Dowar, Youstina Hanna,[...]. Genome Med 2018
41
33

Ovarian cancer.
Ursula A Matulonis, Anil K Sood, Lesley Fallowfield, Brooke E Howitt, Jalid Sehouli, Beth Y Karlan. Nat Rev Dis Primers 2016
331
33

The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy.
Galaxia M Rodriguez, Kristianne J C Galpin, Curtis W McCloskey, Barbara C Vanderhyden. Cancers (Basel) 2018
54
33

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Anniina Färkkilä, Doga C Gulhan, Julia Casado, Connor A Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro,[...]. Nat Commun 2020
68
33

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Jun Zhou, Kathleen M Mahoney, Anita Giobbie-Hurder, Fengmin Zhao, Sandra Lee, Xiaoyun Liao, Scott Rodig, Jingjing Li, Xinqi Wu, Lisa H Butterfield,[...]. Cancer Immunol Res 2017
166
33

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee. N Engl J Med 2017
33

Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance.
Elaine Kilgour, Dominic G Rothwell, Ged Brady, Caroline Dive. Cancer Cell 2020
70
33


Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
Xia Yuan, Jing Zhang, Dan Li, Ye Mao, Fei Mo, Wei Du, Xuelei Ma. Gynecol Oncol 2017
97
33

The intestinal microbiome influences checkpoint blockade.
Cynthia L Sears, Drew M Pardoll. Nat Med 2018
25
33

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
33


Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
627
33

Inflammation is a key contributor to ovarian cancer cell seeding.
Dongyu Jia, Yoshiko Nagaoka, Makoto Katsumata, Sandra Orsulic. Sci Rep 2018
27
33

Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer.
Kristina A Williams, S Intidhar Labidi-Galy, Kathryn L Terry, Allison F Vitonis, William R Welch, Annekathryn Goodman, Daniel W Cramer. Gynecol Oncol 2014
101
33


Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank.
Andrea V Margulis, Manel Pladevall, Nuria Riera-Guardia, Cristina Varas-Lorenzo, Lorna Hazell, Nancy D Berkman, Meera Viswanathan, Susana Perez-Gutthann. Clin Epidemiol 2014
211
33

Prognostic significance of lymphocyte monocyte ratio in patients with ovarian cancer.
Linrui Cai, Yanlin Song, Xia Zhao. Medicine (Baltimore) 2020
4
33


Strategies for modern biomarker and drug development in oncology.
Alan D Smith, Desam Roda, Timothy A Yap. J Hematol Oncol 2014
84
33

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
33

Elevated platelet lymphocyte ratio is a poor prognostic factor in advanced epithelial ovarian cancer.
Seungjoo Chon, Seungho Lee, Dahoe Jeong, Soyi Lim, Kwangbeom Lee, Jinwoo Shin. J Gynecol Obstet Hum Reprod 2021
2
50

A systematic scoping review of adherence to reporting guidelines in health care literature.
Zainab Samaan, Lawrence Mbuagbaw, Daisy Kosa, Victoria Borg Debono, Rejane Dillenburg, Shiyuan Zhang, Vincent Fruci, Brittany Dennis, Monica Bawor, Lehana Thabane. J Multidiscip Healthc 2013
99
33

Ten simple rules for conducting umbrella reviews.
Paolo Fusar-Poli, Joaquim Radua. Evid Based Ment Health 2018
102
33



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.